ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1–SREBP1‐Mediated Lipid Metabolic Reprogramming
Advanced Science · 2026
DOI: 10.1002/advs.202512895 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Xinyue Ma und 12 weiteren Autor:innen. Beteiligte Einrichtung: Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, rho-Associated Kinases, Sterol Regulatory Element Binding Protein 1, Esophageal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Central Guiding Local Science and Technology Development Fund Projects, Young Taishan Scholars Program of Shandong Province.
Abstract (Originalsprache)
Esophageal squamous cell carcinoma (ESCC) remains a highly aggressive malignancy with a 5 year survival rate below 30%, underscoring the urgent need for targeted therapeutic approaches. Here adenosine diphosphate (ADP)‐ribosylation factor‐like protein 5B (ARL5B) is identified as a key candidate oncogene that drives ESCC progression by modulating lipid metabolism via the ras homologous‐associated coiled‐coil containing protein kinase 1(ROCK1)–sterol regulatory element‐binding protein 1 (SREBP1) signaling axis. Through the Cancer Genome Atlas (TCGA) pan‐cancer analysis, ARL5B is initially identified as a promising candidate gene, correlating with advanced tumor, node, metastasis (TNM) stages and poor survival. Functional assays demonstrate that ARL5B knockdown significantly suppresses cell proliferation, invasion, and growth in vivo, while promoting apoptosis. Mechanistically, ARL5B facilitates the activation and nuclear translocation of SREBP1 through ROCK1, thereby enhancing lipogenic programming. Finally, pharmacological inhibition of either ROCK1 or SREBP1 abrogates the oncogenic effects induced by ARL5B overexpression, confirming the functional dependency on this pathway. These results establish ARL5B as a central regulator of lipid metabolism in ESCC and highlight its potential as a therapeutic target for precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, 250012, China.
- Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, 250012, China.
- Jinan Microecological Biomedicine Shandong Laboratory and Shandong Key Laboratory of Brain Health and Function Remodeling, Jinan, 250117, China.
- Institute of Marine Science and Technology, Shandong University, Qingdao, 266237, China.
- Radiology Department, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
ORCID-Profile: Yufeng Cheng
Förderung
- National Natural Science Foundation of China
- Central Guiding Local Science and Technology Development Fund Projects
- Young Taishan Scholars Program of Shandong Province
- Shandong Provincial Natural Science Foundation
- China Postdoctoral Science Foundation
- Natural Science Foundation of Shandong Province
Zitieren
APA
Ma, X., Sun, Y., Mao, H., Huang, C., Li, Z., Wang, T., Jiang, D., Zhang, X., Yuan, Z., Zhang, Z., Cheng, B., Wang, R., & Cheng, Y. (2026). ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1–SREBP1‐Mediated Lipid Metabolic Reprogramming. Advanced Science. https://doi.org/10.1002/advs.202512895
Vancouver
Ma X, Sun Y, Mao H, Huang C, Li Z, Wang T, et al. ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1–SREBP1‐Mediated Lipid Metabolic Reprogramming. Advanced Science. 2026. doi:10.1002/advs.202512895
BibTeX
@article{Ma2026,
author = {Ma, Xinyue and Sun, Yanfei and Mao, Hongyuan and Huang, Chenhan and Li, Zerun and Wang, Tianzi and Jiang, Dizhi and Zhang, Xinyu and Yuan, Zhenyu and Zhang, Zhihui and Cheng, Bo and Wang, Ruiqing and Cheng, Yufeng},
title = {ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1–SREBP1‐Mediated Lipid Metabolic Reprogramming},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202512895}
}
EUVIMED